Final results from the SAUL study are in – International Urology Cancer Summit
International Urology Cancer Summit shared a post on LinkedIn:
“Final results from the SAUL study are in, shedding light on the efficacy and safety of atezolizumab in patients with urinary tract carcinoma (UTC).
Check out the key findings and implications:
Background: SAUL, a single-arm international study, evaluated the use of atezolizumab in patients with pretreated UTC, including those typically excluded from clinical trials due to complex medical conditions.
Methodology: The study enrolled 1004 patients with locally advanced/metastatic UTC, with broad eligibility criteria to mirror real-world scenarios. Patients received atezolizumab every 3 weeks until disease progression or unacceptable toxicity.
Key Findings: The results revealed that atezolizumab demonstrated long-term safety and efficacy, with a median overall survival of 8.6 months. Remarkably, 14% of patients survived for more than 4 years after starting treatment, highlighting its potential benefit in this patient population.
Limitations: While the study provided valuable insights, limitations include the small sample size for certain subgroups.
Clinical Implications: These findings can guide treatment decisions for patients with UTC, particularly those with complex comorbidities, offering hope for prolonged survival and informing multidisciplinary team discussions.
Patient Summary: For patients with UTC, atezolizumab showed promising results in terms of tolerability and survival outcomes, offering a potential treatment option for those who have exhausted other therapies.
Read more about the study here.”
